

Genetic Analyses of DNA-Binding Mutants in the Catalytic Core Domain of Human Immunodeficiency Virus Type 1 Integrase

Richard Lu, Ana Limón,[†] Hina Z. Ghory, and Alan Engelman*

Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, and Department of Pathology, Harvard Medical School, Boston Massachusetts

Received 12 July 2004/Accepted 12 October 2004

The catalytic core domain (CCD) of human immunodeficiency virus type 1 (HIV-1) integrase (IN) harbors the enzyme active site and binds viral and chromosomal DNA during integration. Thirty-five CCD mutant viruses were constructed, paying particular attention to conserved residues in the Phe¹³⁹-Gln¹⁴⁶ flexible loop and abutting Ser¹⁴⁷-Val¹⁶⁵ amphipathic alpha helix that were implicated from previous in vitro work as important for DNA binding. Defective viruses were typed as class I mutants (specifically blocked at integration) or pleiotropic class II mutants (additional particle assembly and/or reverse transcription defects). Whereas HIV-1_{P145A} and HIV-1_{Q146K} grew like the wild type, HIV-1_{N144K} and HIV-1_{Q148L} were class I mutants, reinforcing previous results that Gln-148 is important for DNA binding and uncovering for the first time an important role for Asn-144 in integration. HIV-1_{Q62K}, HIV-1_{H67E}, HIV-1_{N120K}, and HIV-1_{N155K} were also class I mutants, supporting findings that Gln-62 and Asn-120 interact with viral and target DNA, respectively, and suggesting similar integration-specific roles for His-67 and Asn-155. Although results from complementation analyses established that IN functions as a multimer, the interplay between active-site and CCD DNA binding functions was unknown. By using Vpr-IN complementation, we determined that the CCD protomer that catalyzes integration also preferentially binds to viral and target DNA. We additionally characterized E138K as an intramolecular suppressor of Gln-62 mutant virus and IN. The results of these analyses highlight conserved CCD residues that are important for HIV-1 replication and integration and define the relationship between DNA binding and catalysis that occurs during integration in vivo.

An essential step in the retroviral life cycle is the integration of the cDNA made by reverse transcription into a cell chromosome. Integration is mediated by the viral integrase (IN) protein, a specialized DNA recombinase that catalyzes two distinct endonucleolytic reactions during the early phase of infection. The first reaction, 3' processing, occurs shortly after reverse transcription is completed. During 3' processing, human immunodeficiency virus type 1 (HIV-1) IN removes a GT dinucleotide from each end of linear viral cDNA. IN performs its second reaction, DNA strand transfer, after finding a suitable chromosome target for integration. During DNA strand transfer, IN uses the oxygen moieties at the processed 3' ends to cut the target DNA at two 5' phosphates that are separated by 5 bp, which concomitantly joins the 3' ends to the chromosome. The resulting DNA recombination intermediate, with viral 5' ends unattached to the chromosome, is likely repaired by cellular enzymes (see references 16 and 34 for reviews).

Partial proteolysis (24), deletion mutagenesis (9, 70), and functional complementation (23, 69) analyses revealed that HIV-1 IN is comprised of three domains, the N-terminal domain, catalytic core domain (CCD), and C-terminal domain (CTD) (reviewed in reference 29). The CCD (residues 50 to 212 of the 288-residue protein) harbors a triad of invariant carboxylate amino acids (HIV-1 residues Asp-64, Asp-116, and

Glu-152, which form the D,D-35-E motif) that comprises the enzyme active site (7, 20, 21, 24, 46, 49, 67). Results of IN-DNA photo-cross-linking (28, 40, 43), footprinting (19), and in vitro enzyme assays (4, 26, 33, 38, 43, 67) revealed other conserved CCD residues that likely contact viral (28, 33, 40, 41, 43) and target (4, 19, 38, 40, 67) DNA during integration. Specifically, Lys-159, Tyr-143, and Gln-148 cross-linked to viral DNA substrates (28, 43) and IN enzymes with alterations at Lys-159 or Gln-148 were defective in in vitro integration assays (33, 43, 67, 68). Peptides spanning residues 49 to 69 (40) and 51 to 64 (28) cross-linked to viral DNA and IN proteins altered at Gln-62 were sensitive to the concentration of salt in in vitro assays (26, 33), suggesting that Gln-62 also binds HIV-1 DNA (13, 28, 33). Since IN enzymes carrying substitutions of Ser-119 (38) or Asn-120 (67) displayed altered patterns of DNA strand transfer, these residues likely contact target DNA during integration. Since Lys-159, Gln-148, and Tyr-143 interacted with 1-(5-chloroindol-3-yl)-3-hydroxy-(2 *H*-tetrazol-5-yl)-propanone (5CITEP) in an IN-inhibitor cocrystal structure, it was suggested that 5CITEP might inhibit IN activity by interfering with critical IN-DNA contacts that occur during integration (36).

Mixtures of two defective IN mutant proteins can display 3' processing and DNA strand transfer activities, suggesting that IN normally functions as a multimer (23, 69). Since mutants carrying changes in two different active-site residues failed to complement each other, the D,D-35-E active-site residues belong to the same complementation group (69). In other words, integration requires the same protomer within the active multimer to donate all three active-site residues. The organization of the active site to viral and target DNA-binding functions within the CCD, however, has not been probed by complemen-

* Corresponding author. Mailing address: Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, 44 Binney St. Boston, MA 02115. Phone: (617) 632-4361. Fax: (617) 632-3113. E-mail: alan_engelman@dfci.harvard.edu.

[†] Present address: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115.

tation. Although three-dimensional structures of IN-DNA complexes have not been solved, models based on protein fragment structures (14, 71), photo-cross-linking (31, 41), and/or computer simulations (2, 18, 32, 58, 59, 76) have been proposed. Most models posit that the CCD that donates the active site also binds the viral end and the target DNA to which that end will integrate; however, other arrangements are plausible (32, 41). To probe the relationships between these CCD functions, mutants altered for catalytic and presumed viral and target DNA binding activities were tested in complementation assays. This was done in the context of HIV-1 infection by fusing one mutant partner to the virion accessory protein Vpr and testing that fusion in *trans* to defective mutant virus (30, 73). A prerequisite for this strategy was the identification of viral mutants that supported relatively low levels of inherent infectivity. Thus, we began by characterizing a relatively large panel of CCD mutants in assays for HIV-1 spread.

Numerous investigators have analyzed HIV-1 mutants altered at IN active-site residues (3, 10, 25, 27, 39, 47, 48, 54, 55, 57, 60, 62, 63, 65, 72, 74, 75). The resulting class I replication-defective mutants were specifically blocked at integration as evidenced by (i) wild-type (WT) levels of cDNA synthesis in acutely infected cells and (ii) two long terminal repeat (2-LTR)-containing DNA circles that were elevated compared to WT levels, likely due to transient increases in unintegrated DNA pools (3, 25, 39, 48, 54, 57, 60, 62, 72, 75; see reference 22 for a review). In contrast, CCD mutants with changes in potential DNA binding residues have not been systematically analyzed, and unlike active site mutants, wherein any of a number of different missense mutations rendered HIV-1 inactive, the identity of the amino acid substitution had a relatively large impact on the virus replication phenotype. For example, whereas HIV-1_{K159Q} displayed WT replication kinetics (63) and HIV-1_{E157A/K159A} transduced cells 46% as efficiently as the WT (72), HIV-1_{K159P} replicated with an approximate 2-week delay compared to the WT (10), and HIV-1_{K159E} and HIV-1_{K156E/K159E} failed to replicate over a 20-day observation period (43). As another example, HIV-1_{N120L} and HIV-1_{N120E} transduced cells at only about 0.06% of the WT level under conditions where HIV-1_{N120G} supported about 3.3% of the WT transduction activity (48). Cells infected with HIV-1_{K159E}, HIV-1_{K156E/K159E} (43), or HIV-1_{N120L} (48) contained elevated levels of 2-LTR circles, which defined these mutants as class I (reviewed in reference 22). In contrast to the integration-specific class I phenotype, class II IN mutant viruses display particle assembly and/or reverse transcription defects (22).

In this study, 22 CCD residues were targeted by site-directed mutagenesis, yielding 35 mutant viruses. In addition to their potential role in DNA binding, residues were targeted due to 5CITEP binding (36), degree of sequence conservation and surface exposure in crystal structures, and/or previous determination as essential for integration. Our results categorize conserved CCD residues as either dispensable or important for HIV-1 replication and classify defective viruses as either class I or class II. Of note, defective viruses altered at putative DNA contacts were class I mutants, highlighting the integration-specific roles of these residues in HIV-1 replication. Results of Vpr-IN complementation assays indicated that the active CCD protomer within the IN multimer interacts with both viral and target DNA during integration. Revertant mutant viruses were

screened for the presence of second-site mutations, and E138K was characterized as an effective suppressor of Gln-62 mutant viruses and IN. Our results help to define the residues and regions of the IN CCD that engage viral and target DNA during integration.

MATERIALS AND METHODS

Plasmids. Mutations were incorporated into HIV-1_{NL4.3} molecular clones pNL4-3 (1) or pNL43/XmaI (6) using PCR-directed mutagenesis as previously described (25, 51). Previously described mutants were HIV-1_{D116N} (25), HIV-1_{F185K} (42), HIV-1_{K156E}, HIV-1_{K159E}, HIV-1_{K156E/K159E} (43), HIV-1_{D64N/D116N}, and HIV-1_{I1-212} (57). The bacterial expression vector pINSD.His (17) was mutagenized as previously described (26). Plasmid pINSD.His(Q62A) encoding recombinant His-tagged IN_{O62A} has been described (26).

The envelop (Env)-deleted single-round vector pNLX.Luc(R-) was derived from pNLXΔenvCAT (52) as follows. Plasmid pNLX.Luc was generated by amplifying the gene for firefly luciferase (Luc) from pGL3-Basic (Promega Corp., Madison, Wis.) with ClaI- and XhoI-tagged primers, digested, and ligated to ClaI, XhoI-digested pNLXΔenvCAT. To make pNLX(Vpr-), pNL43/XmaI was digested with EcoRI, filled in with Klenow, and religated. Plasmid pNLX.Luc(R-) was built by swapping the 1.6-kb PflMI-NheI fragment from pNLX(Vpr-) for the corresponding fragment in pNLX.Luc. IN mutant derivatives of pNLX.Luc(R-) were built by swapping altered 1.8-kb AgeI-PflMI fragments from pNL4-3 or pNL43/XmaI-based plasmids for the corresponding fragment in pNLX.Luc(R-). The HIV-1_{NL4.3} Env expression vector pNLXE7 was previously described (52).

Plasmid pRL2P-Vpr-IN (73) encoding HIV-1_{YU2}-derived Vpr fused to HIV-1_{SG3} IN was a generous gift from J. Kappes (University of Alabama). Mutations were introduced into pRL2P-Vpr-IN using QuikChange mutagenesis as recommended by the manufacturer (Stratagene, La Jolla, Calif.). DNA sequencing was used to verify the regions of all plasmids that were generated by PCR.

Cells, viruses, and infections. HeLa and 293T cells were grown in Dulbecco's modified Eagle's medium supplemented to contain 10% fetal calf serum (FCS), 100 IU of penicillin per ml, and 0.1 μg of streptomycin sulfate per ml. Jurkat, CEM-12D7, and C8166 T-cells were grown in RPMI 1640 containing 10% FCS, 100 IU of penicillin/ml, and 0.1 μg of streptomycin/ml (RPMI-FCS).

Viruses for spreading-infection and 3' processing assays were derived from HeLa or 293T cells by transfection in the presence of calcium phosphate as previously described (11, 25, 57). The concentration of virus in cell supernatants was determined using a ³²P-based assay for reverse transcriptase (RT) activity (25, 57).

Single-round viruses carrying the HIV-1_{NL4.3} Env for real-time quantitative PCR (RQ-PCR) assays were derived by cotransfecting 293T cells with pNLX.Luc(R-) and pNLXE7 at the ratio of 30:1 using FuGENE 6 (Roche Molecular Biochemicals, Indianapolis, Ind.). Resulting cell supernatants were treated with 40 U of TURBO DNase (Ambion, Austin, Tex.)/ml for 1 h at 37°C to degrade the bulk of plasmid DNA remaining after transfection. Single-round viruses for Vpr-IN complementation studies were assembled by cotransfecting 293T cells with pNLX.Luc(R-), pRL2P-Vpr-IN, and pNLXE7 at the ratio of 30:15:1, using calcium phosphate. Background infectivity measurements of IN mutant viruses in the absence of added Vpr-IN were made by substituting pcDNA3 (Invitrogen, Carlsbad, Calif.) for pRL2P-Vpr-IN during transfection. All single-round viral stocks were normalized for RT content prior to infection. To analyze Vpr-IN incorporation, 293T cells were transfected with pNLX(Vpr-) and pRL2P-Vpr-IN in a 2:1 ratio by using FuGENE6.

For assays of viral spread, Jurkat or CEM-12D7 cells (2 × 10⁶) were infected with WT or IN mutant HIV-1_{NL4.3} (10⁶ RT cpm) for 18 h at 37°C in 0.5 ml of medium unless otherwise noted. The following day, cells were washed with serum-free RPMI 1640 and plated in 5 ml of RPMI-FCS. Cells were split at regular intervals, at which time aliquots of cell supernatants were stored at -20°C for RT assays. CEM-12D7 cells (5 × 10⁶) were infected with 10⁶ RT cpm of WT or IN mutant HIV-1_{NL4.3} for 2-LTR circle PCR analyses as previously described (6).

For RQ-PCR assays, Jurkat cells (4 × 10⁶ per well of a six-well plate) were infected with DNase-treated WT or IN mutant single-round HIV-1_{NLX.Luc(R-)} (5 × 10⁶ RT cpm) by spinoculation for 2 h as previously described (52). Spun cells were washed three times with serum-free RPMI 1640 before plating in 4 ml of RPMI-FCS. For Vpr-IN complementation assays, Jurkat cells (2 × 10⁶) were infected with single-round viruses (5 × 10⁵ RT cpm in 0.5 ml) for 18 h at 37°C, at which time culture volumes were expanded by the addition of 5 ml of RPMI-FCS.

Analysis of HIV-1 proteins. Transfected HeLa cells were radiolabeled with ^{35}S -Met and ^{35}S -Cys as previously described (26). Labeled cells and viruses were lysed and processed for immunoprecipitation, and the resulting immunoprecipitates were analyzed by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and fluorography as previously described (25, 26).

For Western blot analysis of viral particles, 293T cell supernatants were pelleted through 20% sucrose cushions for 120 min at 4°C and 27,000 rpm in a Beckman SW28 rotor. Pellets were lysed in 25 μl of radioimmunoprecipitation assay buffer (140 mM NaCl, 8 mM Na_2HPO_4 , 2 mM NaH_2PO_4 , 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.05% SDS) and normalized for p24 protein content (Alliance HIV-1 p24 ELISA kit; New England Nucleotides, Boston, Mass.), and 2.5 μg of total p24 was analyzed by Western blotting using polyclonal anti-IN antibodies (15).

Analysis of HIV-1 DNA synthesis. (i) **2-LTR circle PCR.** Total DNA was extracted from CEM-12D7 cells 18 h postinfection (hpi), and 10 μl of cell extract was analyzed for levels of HIV-1 2-LTR circles by nested PCR as previously described (6).

(ii) **RQ-PCR.** Total DNA was extracted from infected Jurkat cells 7 and 24 hpi by using the DNeasy kit (QIAGEN, Valencia, Calif.), and 10 μl was amplified by PCR in a 30- μl volume as described previously (51, 54). The PCR primers and Taqman probe were designed to detect total viral cDNA after the second template switch of reverse transcription, and HIV-1 signals were normalized to total cellular DNA using endogenous retrovirus 3 as described previously (51, 54). Parallel infections with Env⁻ viruses were performed to control for residual levels of plasmid DNA that may have resisted DNase treatment, and the resulting PQ-PCR values were subtracted from those obtained with Env⁺ viruses.

Analysis of intracellular 3' processing activity. To determine 3' processing levels, WT and IN mutant preintegration complexes were obtained from cytoplasmic extracts of infected C8166 cells as described previously (11–13). Following deproteinization and precipitation with ethanol, HIV-1 cDNA was cleaved with HaeIII and HindIII and separated by denaturing PAGE. Following electrotransfer, the blot was probed by indirect end labeling as described previously (11, 12). Results were detected by autoradiography and quantified by densitometry (IS-1000 Digital Imaging System; Alpha Innotech Corp., San Leandro, Calif.).

Cloning and sequencing of revertant viruses. Supernatants were prepared from Jurkat cells infected with WT and revertant viruses by Hirt fractionation as previously described (57). Viral sequences amplified from Hirt supernatants by PCR were molecularly cloned as described previously (57).

Expression and purification of recombinant IN protein and in vitro integration assays. IN_{WT} and IN_{O62A} proteins were purified from insoluble fractions of bacterial lysates as previously described (26). IN_{O62A/E138K} and IN_{E138K} were similarly purified and refolded into CN buffer {20 mM HEPES (pH 7.6), 1 mM EDTA, 0.2 M NaCl, 10% (wt/vol) glycerol, 1 mM dithiothreitol, 15 mM [(3-cholamidopropyl)-dimethylammonio]-l-propanesulfonate [CHAPS]}. The N-terminal hexahistidine tag used for protein purification was cleaved from IN using thrombin as previously described (26).

The 5' end of oligonucleotide AE144 (5'-TTTTAGTCAGTGTGGAAAATC TCTAGCAGT) was radiolabeled with T4 polynucleotide kinase as described previously (17). After heat inactivation of the kinase, the complementary single strand AE143 (5'-ACTGCTAGAGATTTCCACACTGACTAAAA) was annealed and the 30-bp DNA substrate was separated from unincorporated nucleide as described previously (17).

In vitro integration reaction mixtures (16 μl) contained 25 mM morpholinepropanesulfonic acid (pH 7.2), 0.1 mg of bovine serum albumin/ml, 10 mM β -mercaptoethanol, 10% glycerol, 25 nM substrate DNA, 0.4 mM CHAPS, 7 mM NaCl, 7.5 mM MnCl_2 , and 0.3 μM IN. The concentration of NaCl in the reactions was varied as appropriate. Reactions were terminated after 60 min at 37°C and analyzed by electrophoresis on denaturing polyacrylamide sequencing gels as previously described (17). Results were visualized by autoradiography and quantitated using densitometry.

Vpr-IN complementation. Cells harvested 48 hpi were washed with phosphate-buffered saline (Mediatech, Hamilton, Va.) and lysed with 75 μl of passive lysis buffer (Promega Corp., Madison, Wis.). Lysates frozen on dry ice and thawed at 37°C were centrifuged at 18,730 $\times g$ for 15 min at 4°C. Supernatants (20 μl) were tested in duplicate for Luc activity using the Luciferase Assay system (Promega Corp.) and an EG&G Berthold Microplate LB 96-V luminometer and Microplate 1 flat-bottom microtiter plate (Thermo Labsystems, Franklin, Mass.). Luc activity was normalized to the total cellular protein concentration as determined by the Bio-Rad protein assay kit (Bio-Rad Laboratories, Hercules, Calif.). Background levels of activity derived from mock infections with Env⁻ HIV-1_{NLX.Luc(R-)} were subtracted from WT and IN mutant values.

RESULTS

Mutagenesis strategy. Twenty-two CCD residues were targeted for mutagenesis, and the resulting mutant viruses were initially assayed for spread in T-cell lines. A major focus of this study was to analyze the phenotypes of viruses mutated at residues proposed to bind DNA, and 16 of the 22 residues fell into this category (Table 1). Overall, residues were chosen for mutagenesis based on one or more of six different selection criteria: the residue (i) was implicated in binding to either viral or target DNA via in vitro activity (33, 43, 67, 68) or photo-cross-linking (28, 40, 41, 43, 56) assays and/or through molecular modeling (58), (ii) interacted with 5CITEP in an IN-inhibitor structure (36), (iii) displayed a high degree of conservation (>95% identity at that position) among a collection of 120 HIV-1 strains (45), (iv) was relatively well conserved among divergent retroviruses (24), (v) was surface exposed in crystal structures (14, 21, 35, 71), and (vi) was previously identified as essential for HIV-1 replication (10, 43, 47, 48, 63, 72). Table 1 lists the 22 residues, their degrees of sequence conservation, the ways in which the different selection criteria applied, and the resulting 35 mutant viruses. Because of this tabulation, selection details will for the most part be sidestepped in text. Yet some examples are noteworthy. Gln-148 was of interest, since this highly conserved residue was implicated in viral DNA (28, 33) and inhibitor (36) binding, and mutant proteins displayed <10 to 54% of IN_{WT} levels of 3' processing and DNA strand transfer activities in in vitro assays (33, 67, 68). Asn-155 was targeted because it too was highly conserved among HIV-1 strains and divergent retroviruses, was implicated via molecular modeling as a potential DNA-binding residue (58), and contacted 5CITEP in the cocrystal structure (36), and mutant proteins displayed only 3 to 18% of IN_{WT} levels of 3' processing, DNA strand transfer, and disintegration activities (33) (Table 1). Neither Gln-148 nor Asn-155 was previously analyzed in assays for HIV-1 infectivity. Since Gln-148 was predictably involved in DNA binding, previously characterized DNA binding mutants HIV-1_{K156E}, HIV-1_{K159E}, and HIV-1_{K156E/K159E} (43) were included for comparison (Table 1). Since active-site residue Glu-152 was also shown to interact with HIV-1 cDNA (33), various Glu-152 mutants were constructed.

Although Asn-144 has not been implicated in DNA binding, this well-conserved residue was targeted because it resides within the Phe¹³⁹-Gln¹⁴⁶ flexible loop region that cross-linked to DNA substrates (40). Of the four loop residues targeted here (Tyr-143, Asn-144, Pro-145, and Gln-146), Tyr-143 cross-linked to viral DNA (28). Certain other residues, such as Asp-55 and Lys-136, were targeted because previous mutants were replication defective (72), yet neither residue was well conserved among divergent retroviruses (Table 1). In particular, Lys-136 was conserved in only 31% of HIV-1 strains, with Gln and Thr predominating at this position approximately 42 and 17% of the time, respectively (45). Mutations were introduced into the NL4-3 strain of HIV-1 (1).

Replication profiles of IN mutant viruses. Jurkat and CEM-12D7 T-cells infected with 10⁶ RT cpm (an approximate multiplicity of infection [MOI] of 0.04; see references 52 and 57) supported peak levels of HIV-1_{NL4-3} replication 4 to 6 days

TABLE 1. Targeted amino acid residues and mutagenesis strategy

Residue	Conservation ^a	Criteria ^b	Reference(s)	Mutation(s) analyzed
Gln-53 ^c	100/33	iii	con ^d	Q53K
Asp-55 ^c	98/10	iii, vi	72	D55A, D55S, D55K
Gln-62	100/76	i, iii, iv, v	14, 28, 33, 40, 71	Q62K
His-67	100/71	i, iii, iv, v	14, 40, 41, 58, 71	H67E, H67Q/K71E
Lys-71	99/48	iii, v	14, 71	K71E
His-114	100/38	i, iii, v	14, 58, 71	H114E
Asn-117	100/90	i, iii, iv, v	14, 33, 58, 71	N117K
Asn-120	100/38	i, iii, v, vi	14, 33, 48, 67, 71	N120L, N120K, N120L/Q148K
Lys-136	31/24	i, v, vi	14, 19, 56, 71, 72	K136A
Glu-138	98/10	i, iii, v	14, 19, 35, 71	E138K
Tyr-143	99/86	i, iii, iv, v	28, 35, 36, 40	Y143G
Asn-144	100/71	iii, iv, v	35	N144K
Pro-145	100/95	i, iii, iv, v	14, 35, 40	P145A
Gln-146	100/81	i, iii, iv, v	14, 35, 40, 58	Q146K
Gln-148	100/62	i, ii, iii, iv, v	14, 28, 33, 35, 36, 67, 68	Q148L, Q148K
Glu-152	99/100	i, ii, iii, iv, v, vi	10, 14, 35, 36, 47, 63, 71, 72	E152D, E152Q, E152K
Ser-153	94/10	i, v	14, 58, 71	S153R
Asn-155	100/76	i, ii, iii, iv, v	14, 33, 36, 58, 71	N155E, N155L, N155K
Lys-156	97/5	i, ii, iii, v, vi	14, 19, 33, 36, 43, 71	K156E
Lys-159	99/100	i, ii, iii, iv, v, vi	14, 19, 33, 36, 43, 71	K159E, K156E/K159E
Asn-184	100/95	iii, iv	con	N184D, N184L
Arg-199	99/38	iii, v, vi	14, 71, 72	R199A, R199E

^a The first number is the percentage at which the residue is found at that position in a collection of 120 HIV-1 strains (45), and the second number is percent identity among 21 different retroviruses (24).

^b The following criteria were utilized: i, implicated via in vitro and/or in silico analyses in DNA binding (19, 28, 33, 40, 41, 43, 56, 58, 67, 68); ii, identified as binding to 5CTEP in an IN-drug cocrystal structure (36); iii, highly conserved (>95%) among HIV-1 isolates; iv, conserved in >50% of retroviral INs; v, surface exposed in crystal structures (14, 35, 71); vi, mutant viruses previously reported as noninfectious (10, 43, 47, 48, 63, 72).

^c Neither Gln-53 nor Asp-55 was visible in X-ray structures.

^d con, conservation. The only selection criterion was degree of sequence conservation.

postinfection (dpi) (Fig. 1). Since substituting Ala for Asp-55 rendered HIV-1_{R7-3} inactive (72), we were a bit surprised to find that NL4-3-based HIV-1_{D55A} replicated similarly to the WT (Fig. 1A). Because of this, a similar substituent, Ser, as well as nonconservative Lys, were tested at this position. Whereas HIV-1_{D55S} grew like the WT, HIV-1_{D55K} was defective (Fig. 1A).

Approximately one-third of the viruses were classified as WT because their replication peaks were reached at the same day or at most 2 days delayed from HIV-1_{NL4-3}. In addition to HIV-1_{D55A} and HIV-1_{D55S}, these included the following: HIV-1_{Q53K} (Fig. 1B), HIV-1_{H114E} (Fig. 1D), HIV-1_{E138K} (Fig. 1E), HIV-1_{Y143G}, HIV-1_{P145A}, and HIV-1_{Q146K} (Fig. 1F), HIV-1_{K136A} and HIV-1_{S153R} (Fig. 1H), and HIV-1_{K71E} (Fig. 1L). A few of the mutants, including HIV-1_{N117K} (Fig. 1D), HIV-1_{Q148K} (Fig. 1G), HIV-1_{K156E} (Fig. 1I), and HIV-1_{N155E} (Fig. 1J), displayed moderate replication delays that ranged from 4 days to 1 week. The following IN mutants replicated with more-serious delays that ranged from 1 to 3 weeks compared to WT replication in repeat experiments: HIV-1_{H67E} (Fig. 1C), HIV-1_{N144K} (Fig. 1D), HIV-1_{N120L} and HIV-1_{N120K} (Fig. 1E), HIV-1_{Q148L} (Fig. 1G), HIV-1_{K159E} (Fig. 1I), HIV-1_{N155K}, HIV-1_{N155L} (Fig. 1J), and HIV-1_{R199A} (Fig. 1K). Numerous mutants in addition to HIV-1_{D55K} were categorized as replication defective, since the cells they infected failed to yield any evidence of virus spread over 2 months of observation. These included the following: HIV-1_{Q62K} (Fig. 1B), HIV-1_{H67Q/K71E} (Fig. 1C), HIV-1_{Q148K/N120L} (Fig. 1G), HIV-1_{K156E/K159E} (Fig. 1I), HIV-1_{R199E} (Fig. 1K), HIV-1_{E152Q}, HIV-1_{N184D}, and HIV-1_{N184L} (Fig. 1L), HIV-1_{E152D}, and HIV-1_{E152K} (data not

shown). Table 2 summarizes mutant viral replication profiles and phenotypic classifications.

Defective IN mutant classification: (i) DNA synthesis. The results in Fig. 1 and Table 2 revealed that the majority of IN mutants (24 of 35) were defective, since either they failed to grow or their replication peaks were delayed minimally 4 days from the WT peak. We next investigated the replication defects for the majority of these viruses. Since cells infected with integration-defective class I mutants contain more 2-LTR circles than WT-infected controls and pleiotropic class II IN mutants are defective for reverse transcription (reviewed in 22), levels of WT and IN mutant 2-LTR circles after acute infection were analyzed. As expected (54, 57), the class I active-site mutant control strain HIV-1_{D64N/D116N} yielded more 2-LTR circles than WT HIV-1_{NL4-3} at 18 hpi (Fig. 2A, compare lane 10 to lane 1). Two of the novel active-site mutants, HIV-1_{E152D} and HIV-1_{E152Q}, also yielded elevated levels of 2-LTR circles (Table 2; also data not shown). Unexpectedly, the other novel active-site mutant (HIV-1_{E152K}) behaved more like the class II CTD deletion mutant strain HIV-1_{I-212} (57), since both yielded minimal levels of 2-LTR circles that were detected only upon prolonged autoradiographic exposure (Fig. 2A, lanes 11 to 13; also data not shown). Thus, HIV-1_{E152K} seemed defective for DNA synthesis. In contrast, most of the other replication-defective mutants, including HIV-1_{Q62K}, HIV-1_{N120K}, HIV-1_{Q148L}, HIV-1_{N155K}, HIV-1_{N155L} (Fig. 2A), HIV-1_{H67E}, HIV-1_{H67Q/K71E}, HIV-1_{N144K}, HIV-1_{Q148K}, HIV-1_{N120L}, and HIV-1_{Q148K/N120L} (Fig. 2B), formed more 2-LTR circles than the WT, which classified these as class I mutant viruses (Table 2). HIV-1_{D55K} (Fig. 2A, lane 2), HIV-1_{R199E}




FIG. 1. Replication kinetics of WT and IN mutant viruses. (A) Aliquots of infected Jurkat T-cell supernatants were assayed for RT activity at the indicated time points. (B and C) Supernatants of CEM-12D7 cells were assayed for RT activity at the indicated times. (D through L) RT profiles of WT and IN mutant viruses in Jurkat cells. Results are representative of a minimum of two independent sets of infections.

(lane 9), HIV-1_{N184L}, and HIV-1_{N184D} (data not shown) yielded less 2-LTR circular DNA than the WT, indicating that like HIV-1_{E152K}, these mutants were defective for reverse transcription. Although HIV-1_{R199A} also yielded fewer 2-LTR circles than the WT (Fig. 2A, lane 8), we note that repeat experiments revealed that these levels were consistently above those detected for HIV-1_{D55K}, HIV-1_{R199E}, HIV-1_{E152K}, and HIV-1₁₋₂₁₂ (Fig. 2; also data not shown).

A subset of the mutants that yielded reduced levels of 2-LTR circles was analyzed for overall HIV-1 levels by RQ-PCR. Primers and Taqman probe were designed to detect products after the second template switch of reverse transcription, and single-round Env⁻ viruses were employed to restrict the spread of the WT control during the 24-h experiment. Since reverse transcription peaks approximately 7 to 8 hpi (12, 13, 44), DNA levels were initially analyzed at 7 hpi. WT HIV-

1_{NLX.Luc(R-)} and the class I mutant HIV-1_{D64N/D116N.Luc(R-)} supported similar levels of reverse transcription (Fig. 2C). In contrast, HIV-1_{D55K.Luc(R-)}, HIV-1_{N184D.Luc(R-)}, HIV-1_{R199E.Luc(R-)}, and HIV-1_{E152K.Luc(R-)} yielded levels that were reduced approximately five- to 10-fold from the WT in repeat experiments (Fig. 2C; also data not shown). To address whether these were absolute or kinetic differences in DNA synthesis, lysates were prepared at 24 hpi. Similar to the results at 7 hpi, HIV-1_{D55K.Luc(R-)}, HIV-1_{N184D.Luc(R-)}, HIV-1_{R199E.Luc(R-)}, and HIV-1_{E152K.Luc(R-)} DNA levels were significantly lower (approximately five- to 10-fold) than those for WT HIV-1_{NLX.Luc(R-)} and HIV-1_{D64N/D116N.Luc(R-)} at 24 hpi (Fig. 2C). Based on this, we conclude that the lower levels of 2-LTR circles detected for class II mutant viruses in Fig. 2A were primarily due to overall reductions in DNA synthesis.

TABLE 2. Summary of IN mutant viral phenotypes

Mutation	Replication ^a	Mutant phenotype ^b
Q53K	++	NA ^c
D55A	++	NA
D55S	++	NA
D55K	-	II
Q62K	-	I
H67E	±	I ^d
H67Q/K71E	-	I
K71E	++	NA
H114E	++	NA
N117K	+	ND ^e
N120L	±	I ^d
N120K	±	I ^d
N120L/Q148K	-	I
K136A	++	NA
E138K	++	NA
Y143G	++	NA
N144K	±	I ^d
P145A	++	NA
Q146K	++	NA
Q148L	±	I ^d
Q148K	+	I ^d
E152D	-	I
E152Q	-	I
E152K	-	II
S153R	++	NA
N155E	+	ND
N155L	±	I ^d
N155K	±	I ^d
K156E	+	I ^f
K159E	+	I ^f
K156E/K159E	-	I ^f
N184D	-	II
N184L	-	II
R199A	±	II ^d
R199E	-	II

^a ++, replication peak detected either the same day or at most 2 days delayed from the WT; +, replication delayed 4 days to 1 week from the WT; ±, peak of virus replication delayed 1 to 3 weeks from the WT; -, replication undetected over 2 months of observation. Values are representative of a minimum of two independent infections.

^b Phenotypic classification based on results in Fig. 1 through 3. Whereas class I mutants are defined as replication-defective viruses that yield 2-LTR circle levels in excess of WT HIV-1 following acute infection, class II mutants display pleiotropic defects at the step(s) of virus assembly and/or reverse transcription (see reference 22 for a review).

^c NA, not applicable, as these viruses replicated similarly to the WT.

^d Although the class I and class II designations are usually reserved for completely dead viruses, here they indicate whether the reason(s) for the replication delays shown in Fig. 1 was primarily due to a specific block in integration (class I phenotype) or whether reduced levels of reverse transcription (class II) may have also contributed.

^e ND, not determined.

^f As determined in reference 43.

(ii) Mutant virus assembly. In addition to the common reverse transcription defect, certain class II IN mutants are defective for the relatively late steps of particle assembly and release (8; reviewed in reference 22). To address whether any of the DNA synthesis-defective mutants displayed late event defects, virus-producing cells were radiolabeled with [³⁵S]Met and [³⁵S]Cys, cell and viral lysates were immunoprecipitated with AIDS patients' antisera, and HIV-1 proteins were analyzed after SDS-PAGE and fluorography. Assembly-release mutants were identified as viruses containing levels of HIV-1 proteins that were significantly lower than their intracellular levels of gene expression.




FIG. 2. WT and IN mutant viral DNA synthesis. (A and B) CEM-12D7 cells infected with the indicated viruses were lysed 18 hpi, and 2-LTR circles were detected by nested PCR as previously described (6). The arrow indicates the 170-bp circle junction product. Results are representative of those obtained in a minimum of two independent sets of infections. (C) Jurkat cells infected with the indicated single-round viruses were lysed at the indicated time points, and total HIV-1 DNA levels quantified by RQ-PCR were normalized to the cellular endogenous retrovirus 3 marker as previously described (51, 54). Error bars represent the variation between duplicate sets of RQ-PCR assays. Results are representative of those obtained in four independent sets of infections. hpi, hours postinfection.

As previously reported (26, 42), the HIV-1_{F185K} class II mutant was released poorly from cells (Fig. 3B, compare lane 5 to lane 1). As predicted from previous analyses of IN deletion mutants (3, 8, 25), the CTD truncation mutant HIV-1₁₋₂₁₂ also released poorly in this assay (Fig. 3A, lane 6 and Fig. 3B, lane 2). Despite these disproportionately low levels of HIV-1_{F185K} and HIV-1₁₋₂₁₂ virion proteins, the mutants were expressed in cells as efficiently as WT HIV-1_{NL4-3} (Fig. 3A, upper panel, lanes 1 and 6; upper panel of Fig. 3B, lanes 1, 2, and 5). Whereas HIV-1_{E152K} (Fig. 3A lower panel, lane 5) and HIV-1_{N184L} (Fig. 3B, lane 3) also displayed release defects, HIV-1_{D55K}, HIV-1_{R199A}, HIV-1_{R199E}, and HIV-1_{N184D} were released from cells similarly to the WT (Fig. 3). We note that assembly-defective class II mutants expressed an increase in the ratio of the Gag processing intermediate capsid-spacer peptide 1 (p25) to mature capsid (p24) (Fig. 3A and B, upper panels), a phenotype associated with a variety of maturation-defective HIV-1 mutants (reference 50 and references therein).




FIG. 3. IN mutant viral assembly and release. (A) HeLa cells were transfected with the indicated plasmid clones, and radioimmunoprecipitated cell (upper panel) and virion (lower panel) lysates were analyzed by SDS-PAGE. (B) Cells transfected with the indicated viral clones were analyzed as for panel A. The migration positions of HIV-1 proteins are indicated. CA-SP1, capsid-spacer peptide 1; CA, capsid; SU, surface; MA, matrix. The minor amount of capsid in lane 6 of Fig. 3B was caused by spillover during gel loading. Similar assembly-release profiles were observed in an independent set of radioimmunoprecipitation assays.

Target DNA binding-defective phenotype of HIV-1_{N120K}. A major goal of this study was to test IN mutants defective for distinct CCD functions for their abilities to complement each other during infection, and identifying numerous class I mutant viruses (Table 2) afforded this possibility. Since recombinant Asn-120 mutant proteins (67) as well as proteins altered at the adjacent Ser-119 residue (38) displayed novel DNA strand transfer patterns in vitro and HIV-1_{N120K} was a class I mutant (Fig. 1E and 2A), the virus was predictably defective for target DNA binding. To investigate this hypothesis, preintegration complexes isolated from acutely infected C8166 cells were quantified for in vivo levels of IN 3' processing activity. If HIV-1_{N120K} was defective for target DNA binding, it should in theory support higher levels of 3' processing activity than class I mutants that were primarily defective for catalysis or viral DNA binding. Indeed, this was the observed phenotype. Whereas HIV-1_{NL4-3} processed about 70% of its U5 end, active-site mutant HIV-1_{D116N} and viral DNA binding mutants HIV-1_{K156E/K159E} and HIV-1_{O62K} failed to detectably process their ends (<3% of U5 processed) (Fig. 4, lanes 1 to 4). In contrast, HIV-1_{N120K} processed about 17% of its end (lane 5). Thus, since (i) HIV-1_{N120K}, HIV-1_{O62K}, HIV-1_{K156E/K159E}, and HIV-1_{D116N} were class I mutant viruses (Fig. 2A) (25, 43) and (ii) HIV-1_{N120K} processed substantially more of its DNA than HIV-1_{D116N}, HIV-1_{K156E/K159E}, or HIV-1_{O62K} (Fig. 4), we inferred that HIV-1_{N120K} was partially defective for target DNA interactions in vivo. This set the stage to test CCD mutants that were predictably defective for viral DNA binding, target DNA binding, or catalysis in complementation assays. Since HIV-1_{N120K} was about fourfold defective for 3' process-




FIG. 4. WT and class I IN mutant 3' processing in cells. The structures of WT and IN mutant U5 plus strands are shown. (+)SSS, cleaved plus-strand strong-stop DNA; Un, 105-nucleotide nonprocessed U5 end; Pro, 103-nucleotide 3' processing product. Similar levels of WT and mutant 3' processing were observed at U3 minus-strand ends (data not shown).

ing activity, we noted that efficient *trans* complementation of target DNA binding might yield 10 to 25% of WT function.

Vpr-IN complementation. A subset of the more deleterious changes that yielded viruses predictably defective for viral DNA binding (O62K and K156E/K159E), target DNA binding (N120K), or catalysis (D64N/D116N) were introduced into the single-round Luc reporter virus HIV-1_{NLX.Luc(R-)}, and O62K and N120K were additionally introduced into pRL2P-Vpr-IN (73). Since Vpr-IN_{V165A} efficiently complemented active site mutant HIV-1 (5, 53), it served as a positive control. Since HIV-1_{V165A} is a CCD class II mutant virus (51, 53), class II mutant fusion proteins Vpr-IN_{R199E} and Vpr-IN_{D55K} were also constructed.

As predicted from their poor performances in spreading-infection assays, HIV-1_{O62K.Luc(R-)}, HIV-1_{K156E/K159E.Luc(R-)}, and HIV-1_{N120K.Luc(R-)} infectivities were near the detection limit of the Luc assay, similar to the case with active-site mutant HIV-1_{D64N/D116N.Luc(R-)} [approximately 0.05 to 0.3% of that for WT HIV-1_{NLX.Luc(R-)}] (Table 3). Vpr-IN_{WT} restored 10 to 30% of HIV-1_{NLX.Luc(R-)} function to HIV-1_{O62K.Luc(R-)}, HIV-1_{K156E/K159E.Luc(R-)}, HIV-1_{N120K.Luc(R-)}, and HIV-1_{D64N/D116N.Luc(R-)} (Table 3). Mutant Vpr-IN activity was reported as percent Vpr-IN_{WT} function. As expected (5, 53), Vpr-IN_{V165A} efficiently complemented active-site mutant HIV-1_{D64N/D116N.Luc(R-)}, and HIV-1_{O62K.Luc(R-)} was also efficiently complemented by Vpr-IN_{V165A} (Table 3). Although Vpr-IN_{V165A} also complemented HIV-1_{K156E/K159E.Luc(R-)} and HIV-1_{N120K.Luc(R-)}, these levels were approximately 5 to 10% of the levels observed with HIV-1_{D64N/D116N.Luc(R-)} and HIV-1_{O62K.Luc(R-)} (Table 3). In contrast to the relatively robust activity of Vpr-IN_{V165A}, Vpr-IN_{O62K} did not complement HIV-1_{D64N/D116N.Luc(R-)}, HIV-1_{O62K.Luc(R-)}, HIV-1_{K156E/K159E.Luc(R-)}, or HIV-1_{N120K.Luc(R-)} (Table 3). Vpr-IN_{N120K} behaved similarly to Vpr-IN_{O62K}; although Vpr-IN_{N120K} weakly complemented HIV-1_{O62K.Luc(R-)} (approximately 3% of Vpr-IN_{WT}), we noted that the reciprocal arrangement yielded negligible activity (Table 3). Based on this, we concluded that O62K, D64N/D116N, K156E/K159E, and N120K belong to the same functional complementation group. We therefore infer that D,D-35-E active site, viral DNA binding, and target DNA binding functions of the CCD are

TABLE 3. Complementation of IN mutant viruses with Vpr-IN^a

IN mutants	% WT activity ^b	Vpr-IN					
		WT ^c	Complementation relative to Vpr-IN _{WT} ^d				
			V165A	Q62K	N120K	R199E	D55K
Q62K	0.32 (0.09)	30.9 (19.4)	181 (17.3)	0.1 (0.1)	3.1 (0.8)	30.4 (15.7)	51.2 (24.9)
K156E/K159E	0.05 (0.00)	17.5 (1.9)	7.9 (1.0)	0.4 (0.4)	1.3 (0.7)	0.7 (0.2)	12.3 (0.1)
D64N/D116N	0.09 (0.01)	9.6 (2.0)	132 (26.7)	0.5 (0.2)	0.7 (0.2)	10.1 (1.8)	25.3 (12.0)
N120K	0.08 (0.05)	20.7 (11.5)	12.5 (0.3)	0.8 (0.9)	1.7 (1.6)	5.4 (5.0)	17.9 (8.0)

^a Values represent an average of a minimum of two infections.

^b Luc activity of the indicated IN mutant virus relative to that of WT HIV-1_{NLX, Luc(R-)} with standard deviations in parentheses.

^c Luc activity of the indicated IN mutant viruses complemented with Vpr-IN_{WT} relative to WT HIV-1_{NLX, Luc(R-)} with standard deviations in parentheses.

^d Percent activity with standard deviations in parentheses.

supplied by the same protomer within the active IN multimer during integration.

Vpr-IN_{R199E} and Vpr-IN_{D55K} were also tested with the various class I mutant viruses. Since Vpr-IN_{R199A} complemented active-site mutant virus (30, 53), it was not surprising that Vpr-IN_{R199E} complemented HIV-1_{D64N/D116N, Luc(R-)} (Table 3). Although Vpr-IN_{R199E} complemented HIV-1_{Q62K, Luc(R-)} and HIV-1_{N120K, Luc(R-)} to levels similar to that observed with HIV-1_{D64N/D116N, Luc(R-)}, it failed to function with HIV-1_{K156E/K159E, Luc(R-)} (Table 3). Vpr-IN_{D55K} was more promiscuous than Vpr-IN_{R199E} in this assay, since it displayed between 12% and approximately 50% of Vpr-IN_{WT} activity with the different class I mutant viruses (Table 3). Although Vpr-IN_{Q62K} efficiently complemented HIV-1_{V165A, Luc(R-)} (53), we note that neither Vpr-IN_{D55K} nor Vpr-IN_{R199E} complemented HIV-1_{V165A, Luc(R-)} (data not shown).

Our results demonstrate that CCD class II mutant Vpr-INS effectively complemented CCD class I mutant viruses under conditions where analogous class I mutant proteins failed to function (Table 3). Our ability to assign various CCD functions to the same IN protomer during postentry integration therefore relied on efficient incorporation of class I and class II Vpr-IN proteins during virus assembly. Although there was little reason to expect differential packaging of different mutant classes, virus particles generated by cotransfecting Vpr-IN expression vectors with HIV-1_{NLX(Vpr-)} were pelleted through sucrose and normalized for p24 content, and Western blots were probed with anti-IN antibodies. Whereas the only reactive HIV-1_{NLX(Vpr-)} band comigrated with recombinant IN protein (Fig. 5, compare lane 2 to lane 1), *trans*-complemented particles contained an additional ~45-kDa product indicative of uncleaved Vpr-IN (lanes 3 to 8) (30, 61, 73). Although class II mutants Vpr-IN_{D55K} and Vpr-IN_{R199E} were incorporated somewhat more efficiently than class I Vpr-IN_{Q62K} and Vpr-IN_{N120K}, the level of class I mutant incorporation was indistinguishable from that of Vpr-IN_{V165A} and Vpr-IN_{WT} (Fig. 5). Based on this, we conclude that CCD class I mutant Vpr-INS do not function with CCD class I mutant viruses due to the lack of postviral entry phenotypic complementation.

Selection and characterization of IN revertant viruses. The experiments in the previous section probed the organization of the CCD through the use of functional complementation, and the results indicated that multiple functions, including metal-based catalysis, viral DNA binding, and target DNA binding, were accomplished by the same protomer within the active IN

multimer. The interplay between different residues in the CCD was also analyzed by selecting and characterizing revertant mutant viruses.

Although some class I mutants, such as HIV-1_{H67E} and HIV-1_{N120K}, showed growth that was significantly delayed compared to that of the WT, their titers eventually approached those of the WT (Fig. 1C and E). We considered two possibilities for these observations. First, the replication delay was a direct consequence of the activity of the mutant IN protein. In other words, replication occurred in the face of the original mutation, and the delay was due to the time required to amass sufficient infection events to drive replication throughout the culture. In the second case, the original mutation, although sufficient to support an initial low level of integration, was insufficient to drive virus spread, and thus, other mutations were required to revert the IN to a more active form. In this case the delay was due to the time required for the initial infection to generate the required mutation(s) through subsequent rounds of reverse transcription and integration. To distinguish between these two scenarios, viruses derived from the peaks of HIV-1_{H67E} (Fig. 1C) and HIV-1_{K159E} (Fig. 1I) replication were passed onto fresh cells. If the first model was true, the passaged viruses would grow with delays similar to those seen in the original infections. If on the other hand additional mutations had occurred, the passaged viruses would replicate at increased rates. Since HIV-1_{Q62A} also grew with an approximate 2-week delay compared to the WT (26), it was included in this analysis. Using a similar selection scheme, we previously




FIG. 5. Vpr-IN incorporation into HIV-1 particles. Lane 1, 50 ng of recombinant IN protein; lane 2, HIV-1_{NLX(Vpr-)} cotransfected with empty vector; lanes 3 to 8, cotransfections with indicated Vpr-IN expression vector; lane 9, mock-transfected cell lysate. The migration positions of Vpr-IN and IN are indicated on the right, and those of molecular mass standards are indicated on the left. Since the weakly reactive ~62-kDa band in lanes 3 to 8 comigrated with dimeric recombinant IN (not shown), we speculate this was cleaved, dimeric IN_{SG3}.

determined that a second CCD substitution (T125A) effectively suppressed the deleterious effects of P109S (64).

Jurkat cells infected with passaged HIV-1_{H67E} and HIV-1_{K159E} revealed cytopathic evidence of viral spread 9 dpi (data not shown). Since HIV-1_{H67E} and HIV-1_{K159E} reached their original growth peaks 21 and 16 dpi, respectively (Fig. 1C and D), we reasoned that the passaged viruses had accumulated new changes. To investigate this, infected cells were lysed by Hirt extraction, and HIV-1 DNA in Hirt supernatants was sequenced after PCR amplification. Whereas HIV-1_{NL4-3} uses an AAG codon for Lys-159, GAA was engineered in HIV-1_{K159E}. The revertant virus harbored AAA at this position, indicating back reversion of the mutation to restore WT HIV-1_{NL4-3}. This was not unexpected for a substitution such as Lys→Glu wherein a single nucleotide change would restore IN_{WT} function. HIV-1_{H67E} contained GAG in place of CAT, and the revertant virus altered this to AAG, indicating that a Lys at position 67 was sufficient for near-IN_{WT} function. Due to what were considered relatively uninformative back reversions of K159E and H67E changes, these revertant viruses were not studied further.

Similar to the results with HIV-1_{H67E} and HIV-1_{K159E}, passaged HIV-1_{O62A(r)} (r for revertant) spread significantly faster than the starting mutant strain (Fig. 6A). Hirt supernatant DNA prepared from HIV-1_{O62A(r)}-infected cells at day 14 postinfection was PCR amplified, and IN coding regions were molecularly cloned prior to sequencing. In one of four cases, the mutant GCG codon underwent two reversional substitutions back to the WT CAG. However, in the other three cases, the mutant GCG codon persisted and a G-to-A transition occurred at nucleotide 4641 of HIV-1_{NL4-3}. This altered the GAA encoding IN residue Glu-138 to the same E138K change that we had included in our starting mutant pool (Table 1 and Fig. 1E). The entire IN coding regions of two of the HIV-1_{O62A(r)} molecular clones were sequenced, which revealed the G-to-A change as the only new alteration in each case.

To investigate whether the E138K change impacted IN_{O62A} function, the G-to-A substitution was incorporated into IN_{WT} and IN_{O62A} bacterial expression constructs, and purified IN_{WT}, IN_{O62A}, IN_{O62A/E138K}, and IN_{E138K} proteins were analyzed in *in vitro* integration assays. Previous studies revealed that IN_{O62A} supported approximately 5 to 20% of IN_{WT} 3' processing and DNA strand transfer activities in reactions containing 25 mM NaCl but substantially less activity (<1 to 3% of IN_{WT}) in the presence of 80 to 90 mM NaCl (26, 33). IN_{WT} converted between 30 and 40% of a 30-bp U5 substrate to the nicked 3' processing product, and this level of activity persisted through a range of NaCl concentration that spanned from 7 to 112 mM (Fig. 6B, upper panel, lanes 1 to 6). Consistent with previous reports, IN_{O62A} converted less of the U5 substrate (8 to 24%) to product than IN_{WT} under low-salt conditions (Fig. 6B, upper panel, compare lanes 8 to 11 to lanes 2 to 5) and only about 5% of the substrate under higher-salt conditions (compare lane 12 to lane 6). As predicted from the near-WT replication profile of HIV-1_{E138K} (Fig. 1E), the activity of the IN_{E138K} enzyme mirrored that of IN_{WT} (Fig. 6B, compare lanes 20 to 24 to lanes 2 to 6). The activity profile of IN_{O62A/E138K} also mirrored that of IN_{WT}. In this case between 15 and 40% of substrate was converted to product, and most notably, IN_{O62A/E138K} displayed the WT level of IN 3' processing ac-




FIG. 6. Identification and characterization of a HIV-1_{O62A} revertant virus. (A) Jurkat cells (5×10^6) infected with 5×10^5 RT cpm of HIV-1_{O62A} produced from (■) transiently transfected HeLa cells (26) or (●) HIV-1_{O62A(r)} obtained from a prior infection of Jurkat cells at 19 dpi were monitored for RT activity at the indicated time points. WT HIV-1_{NL4-3} was derived from transfected HeLa cells. (B) *In vitro* 3' processing (upper panel) and DNA strand transfer (lower panel) activities of WT and IN mutant proteins. IN was omitted from the reaction in lane 1. The reactions in lanes 2 to 6 contained 7, 14, 28, 56, and 112 mM NaCl, respectively (the triangle represents the increase in NaCl concentration). The reactions in lanes 7 to 12, 13 to 18, and 19 to 24 were the same as in lanes 1 to 6 except for the identity of the IN protein, as indicated beneath the gel. The migration positions of the 3' processing substrate and product are marked 30 and 28, respectively. ST, products of strand transfer. Whereas the gel in the upper panel was exposed to X-ray film for 15 min, the lower panel was exposed for 8 h. (C) Jurkat cells (2×10^6) infected with the indicated molecularly cloned viruses (10^6 RT cpm) were monitored for RT activity at the indicated times.

tivity under high-salt conditions (Fig. 6B, upper panel, compare lane 18 to lanes 12 and 6). Longer autoradiographic exposure revealed that the E138K change also restored efficient DNA strand transfer activity to the defective IN_{O62A} enzyme (Fig. 6B, lower panel).

The phenotype of E138K-containing virus was next ana-

lyzed. Since HIV-1_{O62K} was completely defective (Fig. 1B), E138K was tested in the stringent background of HIV-1_{O62K} rather than the HIV-1_{O62A} strain from which it originated. HIV-1_{O62K/E138K} was observed to replicate, although with an approximately 4-day delay from WT replication in repeat experiments (Fig. 6C; also data not shown). Thus, E138K is a bona fide second site suppressor mutation that can revert the deleterious effects of different changes (Ala or Lys) at Gln-62.

DISCUSSION

CCD DNA binding and HIV-1 replication. Although results of in vitro photo-cross-linking (28, 40, 41, 43, 56), integration (33, 43, 67, 68), and in silico analyses (58) have implicated a variety of CCD residues as potentially important for DNA binding (Table 1), just some of these, including Gln-62 (26), Asn-117 (63), Asn-120 (48), Lys-136 (26, 72), Tyr-143 (63, 66, 72), Ser-153 (63), Lys-156 (43, 72), and Lys-159 (10, 43, 63, 72), were previously analyzed for their roles in HIV-1 replication. Whereas some strains, including HIV-1_{K159Q} (63), HIV-1_{K156A} (72), and HIV-1_{K136E} (26), displayed WT replication profiles, other mutants, for example, HIV-1_{K159P} (10), HIV-1_{K156E}, HIV-1_{K159E} (43), and HIV-1_{K136A} (72), were either severely delayed (10) or completely defective (43, 72). To obtain a comprehensive view of the roles of 16 confirmed or proposed CCD DNA-binding residues in HIV-1 replication, 25 mutant viruses were generated (Table 1) and tested in side-by-side infections (Fig. 1). Several conclusions can be drawn from the results. In contrast to active-site mutations wherein a single amino acid substitution is sufficient to render HIV-1 replication defective, almost all singly substituted viral DNA-interacting mutants retained some capacity to replicate, with the lone exception of HIV-1_{O62K} (Fig. 1B to 1J). Since the other purported DNA binding residues that were tested by nonconservative substitution retained some replication capacity (Table 2), we infer that Gln-62 plays a particularly important role in viral DNA end recognition during integration. By analogy, His-67 (Fig. 1C), Asn-120 (Fig. 1E), Gln-148 (Fig. 1G), Lys-159 (Fig. 1I), and Asn-155 (Fig. 1J) also play important roles in HIV-1 replication. Whereas single missense mutants derived from these residues replicated to some degree, we note that double mutants HIV-1_{H67Q/K71E} (Fig. 1C), HIV-1_{Q148K/N120L} (Fig. 1G), and HIV-1_{K156E/K159E} (Fig. 1I) were completely defective. In contrast, since HIV-1_{Y143G} grew as did the WT (Fig. 1F) and HIV-1_{N117K} showed just marginally delayed growth (Fig. 1D), we conclude that neither Asn-117 nor Tyr-143 played a significant role in HIV-1 replication under these conditions. We note that Tyr-143 was suggested to play a particularly important role during macrophage infection (66), a cell type that was not tested here. Similarly, we were unable to ascertain a role for Lys-136 in HIV-1 replication (Fig. 1H) (26). Since Wiskerchen and Muesing (72) previously reported that the K136A change rendered HIV-1_{R7-3} replication defective, Lys-136 could play a strain-dependent role in replication. The same may hold true for Asp-55, since we determined that NL4-3-based HIV-1_{D55A} grew as did WT (Fig. 1A) yet R7-3-based HIV-1_{D55A} was replication defective (72). Other aspects of tissue culture infections could also contribute to disparate results. For example, whereas CEM-12D7 cells infected at an approximate MOI of 10^{-3} failed to support replication of




FIG. 7. Structural summary of CCD residues important and dispensable for HIV-1 replication. The B monomer of the IN CCD dimer from reference 35 is shown (Protein Data Bank identifier 1BIS). The following color code was used: red, active-site residues (Asp-64, Asp-116, and Glu-152); blue, residues that cross-linked to viral DNA substrates (Tyr-143, Gln-148, and Lys-159; references 28 and 43) and/or when mutated yielded class I IN mutant viruses (see Fig. 1 and 2) (43); green, residues that when mutated yielded viruses displaying WT replication kinetics; yellow, Glu-138; magenta, residues that predictably interact with target DNA (38, 67). The amphipathic alpha-helix is labeled helix 4.

HIV-1_{K156E} or HIV-1_{K159E} over 20 days of observation (43), Jurkat cells infected at an MOI of 0.04 revealed HIV-1_{K156E} and HIV-1_{K159E} replication peaks at 12 and 16 dpi, respectively (Fig. 1I).

Our results help in understanding conserved residues and structural features of the CCD Phe¹³⁹-Gln¹⁴⁶ flexible loop and abutting Ser¹⁴⁷-Val¹⁶⁵ amphipathic alpha-helix, which are likely important for DNA binding during HIV-1 replication. In terms of the alpha-helix, previous in vitro work indicated that the polar face of the amphipathic structure interacted with viral DNA (76), and our work with mutant viruses supports these findings. For example, Gln-148, Glu-152, Asn-155, and Lys-159 reside on the same side of the helix (Fig. 7, upward face of helix 4 as drawn).

Since class I mutant HIV-1_{N155K} (Fig. 1J) grew significantly slower than HIV-1_{K156E} (Fig. 1I) and Asn-155 contacted 5CITEP in the cocrystal structure (36), we speculate that Asn-155 interacts with HIV-1 cDNA during integration. This conclusion is in agreement with the results of a molecular modeling study that proposed that Asn-155 might bind DNA (58). Ser-153, which like other helix 4 residues was well conserved among HIV-1 isolates (Table 1), instead jutted down from the underside of the helix (Fig. 7). Whereas Ser-153 was dispensable for HIV-1 replication, alterations of the conserved residues positioned atop helix 4 yielded class I phenotypic viruses (Table 2).

The Phe¹³⁹-Gln¹⁴⁶ flexible loop cross-linked to DNA substrates (40), and Tyr-143 was subsequently shown to cross-link to the adenosine at the 5' end of the nontransferred U5 minus-strand (28). The other loop residues targeted here, Asn-144, Pro-145, and Gln-146, were similar to Tyr-143 in that they were

well conserved among HIV-1 strains and divergent retroviruses (Table 1). However, out of these four highly conserved residues, only Asn-144 played a significant role in HIV-1 replication (Fig. 1D and F). Since HIV-1_{N144K} synthesized more 2-LTR circles than the WT (Fig. 2B), our results indicate that Asn-144 plays a specific role in integration. However, it is unclear if this includes DNA binding. From the structure-based pattern of required residues, one can deduce an extended pocket that encompasses the approximate lower half of the molecule, as drawn in Fig. 7, to which viral DNA might bind. Asn-144 seems to jut away from this pocket. However, it should be noted that due to its flexibility, the loop is generally not observed in CCD structures, and the precise locations of loop side chains differ dramatically among the few structures where they are observed (7, 35, 37). Despite these limitations, Gln-146 may be dispensable for HIV-1 replication because it points down toward the underside of helix 4 (Fig. 7).

Although results of an *in vitro* footprinting assay indicated that DNA strongly protected Glu-138 from proteolysis (19), HIV-1_{E138K} grew similarly to the WT, indicating that Glu-138 does not play an important role in HIV-1 replication under these conditions (Fig. 1E). Interestingly, E138K was identified as an intramolecular mutation that suppressed the adverse effects of Q62A and Q62K changes (Fig. 6). In the CCD structure, Glu-138 is positioned toward oppositely charged Lys-136, noticeably away from Gln-62 (Fig. 7). Because of this, we speculate that substituting Lys for Glu-138 would redirect the mutant side chain away from Lys-136, which might orient it toward Gln-62 and in doing so directly compensate for a loss of DNA binding incurred through Gln-62 substitutions.

The roles of other conserved CCD residues in HIV-1 replication. Five residues, Gln-53, Asp-55, Lys-71, Asn-184, and Arg-199, that were neither implicated in DNA binding nor part of the Phe¹³⁹-Gln¹⁴⁶ flexible loop, were also targeted in this study. Although Gln-53 was invariant among HIV-1 strains (Table 1), HIV-1_{O53K} grew as did the WT (Fig. 1B), and thus, our assay system did not reveal a role for Gln-53 in HIV-1 replication. The same can be said for highly conserved Lys-71 (Table 1 and Fig. 1L). In contrast, HIV-1_{D55K}, HIV-1_{N184D}, HIV-1_{N184L}, and HIV-1_{R199E} were replication defective (Fig. 1A, K, and L). Since each of these mutants synthesized significantly less cDNA than the WT (Fig. 2 and data not shown) and HIV-1_{N184L} was released less efficiently than the WT from HeLa cells (Fig. 3B), these viruses were typed as pleiotropic class II mutants. The results of Asp-55 mutagenesis are reminiscent of our previous findings with Phe-185 (26). In that paper we determined that HIV-1_{F185H} replicated as did the WT and that HIV-1_{F185K}, HIV-1_{F185A}, and HIV-1_{F185L} were replication-defective class II mutants (26; see reference 22 for a review). Somewhat surprisingly, HIV-1_{E152K} was also a class II mutant (Fig. 2A and 3A; Table 2). Since HIV-1_{E152D} and HIV-1_{E152Q} were class I viruses (Table 1), these results demonstrate that different substitutions of the same residue can yield either the class I or class II mutant phenotype.

Functional organization of the HIV-1 IN CCD. Vpr-IN complementation was used to probe the functional relationship between catalysis and viral and target DNA binding that occurs during integration. For this we needed viral mutants for each of these functions that supported relatively low levels of inherent infectivity. By characterizing a large collection of

CCD mutants in assays for viral spread, HIV-1_{O62K}, HIV-1_{K156E/K159E}, and HIV-1_{N120K} were determined to meet these requirements. Since Vpr-IN_{O62K} complemented HIV-1_{V165A.Luc(R-)} (53) but failed to complement either HIV-1_{K156E/K159E.Luc(R-)} or HIV-1_{D64N/D116N.Luc(R-)}, our results indicate that different DNA-binding residues, such as Gln-62 and Lys-159, originate from the same functional protomer and that the active CCD binds to the viral DNA end that it functionally integrates. This result enforces previous IN-DNA models, which invariably predicted that the active CCD also bound to the viral DNA that it processed and joined to target DNA (2, 14, 18, 31, 32, 41, 58, 59, 71). Despite this “*cis*” requirement for active-site and CCD viral DNA-binding functions to reside within the same protomer, we note that the CTD’s viral DNA end binding function is donated by a separate IN molecule (14, 31).

HIV-1_{N120K} was a class I mutant (Fig. 2A, lane 4) that processed significantly more of its 3’ ends than other class I mutants, including active-site mutant HIV-1_{D116N} and viral DNA-binding mutants HIV-1_{O62K} and HIV-1_{K156E/K159E} (Fig. 4). Based on these results and previous observations that recombinant IN proteins altered at Asn-120 or the adjacent Ser-119 displayed altered patterns of DNA strand transfer (38, 67), we inferred that HIV-1_{N120K} was in part defective for target DNA binding *in vivo*. Since Vpr-IN_{O62K} did not complement HIV-1_{N120K.Luc(R-)} and Vpr-IN_{N120K} failed to appreciably complement HIV-1_{O62K.Luc(R-)}, HIV-1_{K156E/K159E.Luc(R-)}, or HIV-1_{D64N/D116N.Luc(R-)}, our results indicate that the active protomer within the IN multimer that binds and processes viral DNA also binds the chromosomal DNA into which it integrates. Although we inferred from *in vitro* studies that Gln-62, Asn-120, and Lys-159 directly contact DNA, we have not extensively characterized biochemical properties of recombinant proteins and because of this cannot rule out that disruption of other IN functions (for example, multimerization) contributed to the class I mutant phenotypes described here.

In conclusion, our results prioritized the importance of a number of conserved CCD residues that were previously implicated in DNA binding for their roles in HIV-1 replication. Together with the results of Vpr-IN complementation, our results were used to refine the regions of the active CCD protomer that interact with viral and target DNA during integration (Fig. 7). Precise structural delineation of the active IN-DNA complex is expected to aid the design of inhibitors that block HIV-1 replication before the virus has the chance to integrate into chromosomal DNA.

ACKNOWLEDGMENTS

We thank J. Kappes for his generation donation of plasmid DNA, M. Farzan for his help in constructing Fig. 7, and Y. Liu for her technical assistance during the early phase of this project.

This work was supported by National Institutes of Health grant AI39394. Core facilities were supported by a Center for AIDS Research grant (AI28691) and the Dana-Farber Cancer Institute/Harvard Cancer Center.

REFERENCES

- Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. *J. Virol.* 59:284-291.
- Adesokan, A. A., V. A. Roberts, K. W. Lee, R. D. Lins, and J. M. Briggs. 2004.

- Prediction of HIV-1 integrase/viral DNA interactions in the catalytic domain by fast molecular docking. *J. Med. Chem.* **47**:821–828.
3. **Ansari-Lari, M. L., L. A. Donehower, and R. A. Gibbs.** 1995. Analysis of human immunodeficiency virus type 1 integrase mutants. *Virology* **211**:332–335.
 4. **Appa, R. S., C.-G. Shin, P. Lee, and S. A. Chow.** 2001. Role of the non-specific DNA binding region and α helices within the core domain of retroviral integrase in selecting target DNA sites for integration. *J. Biol. Chem.* **276**:45848–45855.
 5. **Bouyac-Bertoia, M., J. D. Dvorin, R. A. M. Fouchier, Y. Jenkins, B. E. Meyer, L. I. Wu, M. Emerman, and M. H. Malim.** 2001. HIV-1 infection requires a functional integrase NLS. *Mol. Cell* **7**:1025–1035.
 6. **Brown, H. E. V., H. Chen, and A. Engelman.** 1999. Structure-based mutagenesis of the human immunodeficiency virus type 1 DNA attachment site: effects on integration and cDNA synthesis. *J. Virol.* **73**:9011–9020.
 7. **Bujacz, G., J. Alexandratos, Z. L. Qing, C. Clement-Mella, and A. Wlodawer.** 1996. The catalytic domain of human immunodeficiency virus integrase: ordered active site in the F185H mutant. *FEBS Lett.* **398**:175–178.
 8. **Bukovsky, A., and H. Göttlinger.** 1996. Lack of integrase can markedly affect human immunodeficiency virus type 1 particle production in the presence of an active viral protease. *J. Virol.* **70**:6820–6825.
 9. **Bushman, F. D., A. Engelman, I. Palmer, P. Wingfield, and R. Craigie.** 1993. Domains of the integrase protein of human immunodeficiency virus type 1 responsible for polynucleotidyl transfer and zinc binding. *Proc. Natl. Acad. Sci. USA* **90**:3428–3432.
 10. **Cannon, P. M., W. Wilson, E. Byles, S. M. Kingsman, and A. J. Kingsman.** 1994. Human immunodeficiency virus type 1 integrase: effect on viral replication of mutations at highly conserved residues. *J. Virol.* **68**:4768–4775.
 11. **Chen, H., and A. Engelman.** 2000. Characterization of a replication-defective human immunodeficiency virus type 1 *att* site mutant that is blocked after the 3' processing step of retroviral integration. *J. Virol.* **74**:8188–8193.
 12. **Chen, H., and A. Engelman.** 2001. Asymmetric processing of human immunodeficiency virus type 1 cDNA in vivo: implications for functional end coupling during the chemical steps of DNA transposition. *Mol. Cell. Biol.* **21**:6758–6767.
 13. **Chen, H., S.-Q. Wei, and A. Engelman.** 1999. Multiple integrase functions are required to form the native structure of the human immunodeficiency virus type 1 intasome. *J. Biol. Chem.* **274**:17358–17364.
 14. **Chen, J. C.-H., J. Krucinski, L. J. W. Miercke, J. S. Finer-Moore, A. H. Tang, A. D. Leavitt, and R. M. Stroud.** 2000. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. *Proc. Natl. Acad. Sci. USA* **97**:8233–8238.
 15. **Cherepanov, P., W. Plummers, A. Claeys, P. Proost, E. De Clercq, and Z. Debyser.** 2000. High-level expression of active HIV-1 integrase from a synthetic gene in human cells. *FASEB J.* **14**:1389–1399.
 16. **Craigie, R.** 2002. Retroviral DNA integration, p. 613–630. *In* N. L. Craig, R. Craigie, M. Gellert, and A. M. Lambowitz (ed.), *Mobile DNA II*. ASM Press, Washington, D.C.
 17. **Craigie, R., A. B. Hickman, and A. Engelman.** 1995. Integrase, p. 53–71. *In* J. Karn (ed.), *HIV: a practical approach*, vol. 2. Oxford University Press, Oxford, United Kingdom.
 18. **De Luca, L., A. Pedretti, G. Vistoli, M. L. Barreca, L. Villa, P. Monforte, and A. Chimirri.** 2003. Analysis of the full-length integrase-DNA complex by a modified approach for DNA docking. *Biochem. Biophys. Res. Commun.* **310**:1083–1088.
 19. **Dirac, A. M. G., and J. Kjems.** 2001. Mapping DNA-binding sites of HIV-1 integrase by protein footprinting. *Eur. J. Biochem.* **268**:743–751.
 20. **Drelich, M., R. Wilhelm, and J. Mous.** 1992. Identification of amino acid residues critical for endonuclease and integration activities of HIV-1 IN protein in vitro. *Virology* **188**:459–468.
 21. **Dyda, F., A. B. Hickman, T. M. Jenkins, A. Engelman, R. Craigie, and D. R. Davies.** 1994. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. *Science* **266**:1981–1986.
 22. **Engelman, A.** 1999. In vivo analysis of retroviral integrase structure and function. *Adv. Virus Res.* **52**:411–426.
 23. **Engelman, A., F. D. Bushman, and R. Craigie.** 1993. Identification of discrete functional domains of HIV-1 integrase and their organization within an active multimeric complex. *EMBO J.* **12**:3269–3275.
 24. **Engelman, A., and R. Craigie.** 1992. Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro. *J. Virol.* **66**:6361–6369.
 25. **Engelman, A., G. Englund, J. M. Orenstein, M. A. Martin, and R. Craigie.** 1995. Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. *J. Virol.* **69**:2729–2736.
 26. **Engelman, A., Y. Liu, H. Chen, M. Farzan, and F. Dyda.** 1997. Structure-based mutagenesis of the catalytic domain of human immunodeficiency virus type 1 integrase. *J. Virol.* **71**:3507–3514.
 27. **Englund, G., T. S. Theodore, E. O. Freed, A. Engelman, and M. A. Martin.** 1995. Integration is required for productive infection of monocyte-derived macrophages by human immunodeficiency virus type 1. *J. Virol.* **69**:3216–3219.
 28. **Esposito, D., and R. Craigie.** 1998. Sequence specificity of viral DNA end binding by HIV-1 integrase reveals critical regions for protein-DNA interaction. *EMBO J.* **17**:5832–5843.
 29. **Esposito, D., and R. Craigie.** 1999. HIV integrase structure and function. *Adv. Virus Res.* **52**:319–333.
 30. **Fletcher, T. M., III, M. A. Soares, S. McPhearson, H. Hui, M. Wiskerchen, M. A. Muesing, G. M. Shaw, A. D. Leavitt, J. D. Boeke, and B. H. Hahn.** 1997. Complementation of integrase function in HIV-1 virions. *EMBO J.* **16**:5123–5138.
 31. **Gao, K., S. L. Butler, and F. Bushman.** 2001. Human immunodeficiency virus type 1 integrase: arrangement of protein domains in active cDNA complexes. *EMBO J.* **20**:3565–3576.
 32. **Gao, K., S. Wong, and F. Bushman.** 2004. Metal binding by the D₁DX₃₅E motif of human immunodeficiency virus type 1 integrase: selective rescue of Cys substitutions by Mn²⁺ in vitro. *J. Virol.* **78**:6715–6722.
 33. **Gerton, J. L., S. Ohgi, M. Olsen, J. DeRisi, and P. O. Brown.** 1998. Effects of mutations in residues near the active site of human immunodeficiency virus type 1 integrase on specific enzyme-substrate interactions. *J. Virol.* **72**:5046–5055.
 34. **Goff, S. P.** 2001. *Retroviridae: the retroviruses and their replication*, p. 1871–1939. *In* D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), *Fields virology*, 4th ed. Lippincott Williams & Wilkins, Philadelphia, Pa.
 35. **Goldgur, Y., F. Dyda, A. B. Hickman, T. M. Jenkins, R. Craigie, and D. R. Davies.** 1998. Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. *Proc. Natl. Acad. Sci. USA* **95**:9150–9154.
 36. **Goldgur, Y., R. Craigie, G. H. Cohen, T. Fujiwara, T. Yoshinaga, T. Fujishita, H. Sugimoto, T. Endo, H. Murai, and D. R. Davies.** 1999. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral design. *Proc. Natl. Acad. Sci. USA* **96**:13040–13043.
 37. **Greenwald, J., V. Le, S. L. Butler, F. D. Bushman, and S. Choe.** 1999. The mobility of an HIV-1 integrase active site loop is correlated with catalytic activity. *Biochemistry* **38**:8892–8898.
 38. **Harper, A. L., L. M. Skinner, M. Sudol, and M. Katzman.** 2001. Use of patient-derived human immunodeficiency virus type 1 integrases to identify a protein residue that affects target site selection. *J. Virol.* **75**:7756–7762.
 39. **Hazuda, D. J., P. Felock, M. Witmer, A. Wolfe, K. Stillmock, J. A. Grobler, A. Espeseth, L. Gabryelski, W. Schleif, C. Blau, and M. D. Miller.** 2000. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. *Science* **287**:646–650.
 40. **Heuer, T. S., and P. O. Brown.** 1997. Mapping features of HIV-1 integrase near selected sites on viral and target DNA molecules in an active enzyme-DNA complex by photo-cross-linking. *Biochemistry* **36**:10655–10665.
 41. **Heuer, T. S., and P. O. Brown.** 1998. Photo-cross-linking studies suggest a model for the architecture of an active human immunodeficiency virus type 1 integrase-DNA complex. *Biochemistry* **37**:6667–6678.
 42. **Jenkins, T. M., A. Engelman, R. Ghirlando, and R. Craigie.** 1996. A soluble active mutant of HIV-1 integrase: involvement of both the core and C-terminal domains in multimerization. *J. Biol. Chem.* **271**:7712–7718.
 43. **Jenkins, T. M., D. Esposito, A. Engelman, and R. Craigie.** 1997. Critical contacts between HIV-1 integrase and viral DNA identified by structure-based analysis and photo crosslinking. *EMBO J.* **16**:6849–6859.
 44. **Kim, S., R. Byrn, J. Groopman, and D. Baltimore.** 1989. Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. *J. Virol.* **63**:3708–3713.
 45. **Kuiken, C. L., B. Foley, E. Freed, B. Hahn, B. Korber, P. A. Marx, F. McCutchan, J. W. Mellors, and S. Wolinsky.** 2002. HIV sequence compendium 2002. Report no. LA-UR 03-3564. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, N.Mex.
 46. **Kulkosky, J., K. S. Jones, R. A. Katz, J. P. G. Mack, and A. M. Skalka.** 1992. Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases. *Mol. Cell. Biol.* **12**:2331–2338.
 47. **LaFemina, R. L., C. L. Schneider, H. L. Robbins, P. L. Callahan, K. LeGrow, E. Roth, W. A. Schleif, and E. A. Emini.** 1992. Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. *J. Virol.* **66**:7414–7419.
 48. **Leavitt, A. D., G. Robles, N. Alesandro, and H. E. Varmus.** 1996. Human immunodeficiency virus type 1 integrase mutants retain in vitro integrase activity yet fail to integrate viral DNA efficiently during infection. *J. Virol.* **70**:721–728.
 49. **Leavitt, A. D., L. Shiu, and H. E. Varmus.** 1993. Site-directed mutagenesis of HIV-1 integrase demonstrates differential effects on integrase function in vitro. *J. Biol. Chem.* **268**:2113–2119.
 50. **Li, F., R. Goila-Gaur, K. Salzwedel, N. R. Kilgore, M. Reddick, C. Matalana, A. Castillo, D. Zoumplis, D. E. Martin, J. M. Orenstein, G. P. Alloway, E. O. Freed, and C. T. Wild.** 2003. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. *Proc. Natl. Acad. Sci. USA* **100**:13555–13560.
 51. **Limón, A., E. Devroe, R. Lu, H. Z. Ghory, P. A. Silver, and A. Engelman.** 2002. Nuclear localization of human immunodeficiency virus type 1 preintegration complexes (PICs): V165A and R166A are pleiotropic integrase mu-

- tants primarily defective for integration, not PIC nuclear import. *J. Virol.* **76**:10598–10607.
52. **Limón, A., N. Nakajima, R. Lu, H. Z. Ghory, and A. Engelman.** 2002. Wild-type levels of nuclear localization and human immunodeficiency virus type 1 replication in the absence of the central DNA flap. *J. Virol.* **76**:12078–12086.
 53. **Lu, R., A. Limón, E. Devroe, P. A. Silver, P. Cherepanov, and A. Engelman.** 2004. Class II integrase mutants with changes in putative nuclear localization signals are primarily blocked at a postnuclear entry step of human immunodeficiency virus type 1 replication. *J. Virol.* **78**:12735–12746.
 54. **Lu, R., N. Nakajima, W. Hofmann, M. Benkirane, K. Teh-Jeang, J. Sodroski, and A. Engelman.** 2004. Simian virus 40-based replication of catalytically inactive human immunodeficiency virus type 1 integrase mutants in nonpermissive T cells and monocyte-derived macrophages. *J. Virol.* **78**:658–668.
 55. **Masuda, T., V. Planelles, P. Krogstad, and I. S. Y. Chen.** 1995. Genetic analysis of human immunodeficiency virus type 1 integrase and the U3 *att* site: unusual phenotype of mutants in the zinc finger-like domain. *J. Virol.* **69**:6687–6696.
 56. **Mazumder, A., N. Neamati, A. A. Pilon, S. Sunder, and Y. Pommier.** 1996. Chemical trapping of ternary complexes of human immunodeficiency virus type 1 integrase, divalent metal, and DNA substrates containing an abasic site. *J. Biol. Chem.* **271**:27330–27338.
 57. **Nakajima, N., R. Lu, and A. Engelman.** 2001. Human immunodeficiency virus type 1 replication in the absence of integrase-mediated DNA recombination: definition of permissive and nonpermissive T-cell lines. *J. Virol.* **75**:7944–7955.
 58. **Perryman, A. L., and J. A. McCammon.** 2002. Autodocking dinucleotides to the HIV-1 integrase core domain: exploring possible binding sites for viral and genomic DNA. *J. Med. Chem.* **45**:5624–5627.
 59. **Podtelezhnikov, A. A., K. Gao, F. D. Bushman, and J. A. McCammon.** 2003. Modeling HIV-1 integrase complexes based on their hydrodynamic properties. *Biopolymers* **68**:110–120.
 60. **Poon, B., and I. S. Y. Chen.** 2003. Human immunodeficiency virus type 1 (HIV-1) Vpr enhances expression from unintegrated HIV-1 DNA. *J. Virol.* **77**:3962–3972.
 61. **Priet, S., J.-M. Navarro, G. Querat, and J. Sire.** 2003. Reversion of the lethal phenotype of an HIV-1 integrase mutant virus by overexpression of the same integrase mutant protein. *J. Biol. Chem.* **278**:20724–20730.
 62. **Saenz, D. T., N. Loewen, M. Peretz, T. Whitwam, R. Barraza, K. G. Howell, J. M. Holmes, M. Good, and E. M. Poeschla.** 2004. Unintegrated lentivirus DNA persistence and accessibility to expression in nondividing cells: analysis with class I integrase mutants. *J. Virol.* **78**:2906–2920.
 63. **Shin, C.-G., B. Taddeo, W. A. Haseltine, and C. M. Farnet.** 1994. Genetic analysis of the human immunodeficiency virus type 1 integrase protein. *J. Virol.* **68**:1633–1642.
 64. **Taddeo, B., F. Carlini, P. Verani, and A. Engelman.** 1996. Reversion of a human immunodeficiency virus type 1 integrase mutant at a second site restores enzyme function and virus infectivity. *J. Virol.* **70**:8277–8284.
 65. **Taddeo, B., W. A. Haseltine, and C. M. Farnet.** 1994. Integrase mutants of human immunodeficiency virus type 1 with a specific defect in integration. *J. Virol.* **68**:8401–8405.
 66. **Tsurutani, N., M. Kubo, Y. Maeda, T. Ohashi, N. Yamamoto, M. Kannagi, and T. Masuda.** 2000. Identification of critical amino acid residues in human immunodeficiency virus type 1 IN required for efficient proviral DNA formation at steps prior to integration in dividing and nondividing cells. *J. Virol.* **74**:4795–4806.
 67. **van Gent, D. C., A. A. M. O. Groeneger, and R. H. A. Plasterk.** 1992. Mutational analysis of the integrase protein of human immunodeficiency virus type 2. *Proc. Natl. Acad. Sci. USA* **89**:9598–9602.
 68. **van Gent, D. C., A. A. M. O. Groeneger, and R. H. A. Plasterk.** 1993. Identification of amino acids in HIV-1 integrase involved in site-specific hydrolysis and alcoholysis of viral DNA termini. *Nucleic Acids Res.* **21**:3373–3377.
 69. **van Gent, D. C., C. Vink, A. A. M. O. Groeneger, and R. H. A. Plasterk.** 1993. Complementation between HIV integrase proteins mutated in different domains. *EMBO J.* **12**:3261–3267.
 70. **Vink, C., A. A. M. O. Groeneger, and R. H. A. Plasterk.** 1993. Identification of the catalytic and DNA-binding region of human immunodeficiency virus type 1 integrase protein. *Nucleic Acids Res.* **21**:1419–1425.
 71. **Wang, J.-Y., H. Ling, W. Yang, and R. Craigie.** 2001. Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. *EMBO J.* **20**:7333–7343.
 72. **Wiskerchen, M., and M. A. Muesing.** 1995. Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells. *J. Virol.* **69**:376–386.
 73. **Wu, X., H. Liu, H. Xiao, J. A. Conway, E. Hunter, and J. C. Kappes.** 1997. Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein. *EMBO J.* **16**:5113–5122.
 74. **Wu, Y., and J. W. Marsh.** 2001. Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA. *Science* **293**:1503–1506.
 75. **Wu, Y., and J. W. Marsh.** 2003. Early transcription from nonintegrated DNA in human immunodeficiency virus infection. *J. Virol.* **77**:10376–10382.
 76. **Zargarian, L., M. S. Benleumi, J. G. Renisio, H. Merad, R. G. Maroun, F. Wieber, O. Mauffret, H. Porumb, F. Troalen, and S. Fermandjian.** 2003. Strategy to discriminate between high and low affinity bindings of human immunodeficiency virus, type 1 integrase to viral DNA. *J. Biol. Chem.* **278**:19966–19973.